Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Anti-BCMA CAR T Cells + Cyclophosphamide + Fludarabine + LY3039478|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Anti-BCMA CAR T Cells||CART-BCMA|CT053||Anti-BCMA CAR T Cells are T-cells that express a chimeric antigen receptor targeting B-cell maturation antigen (BCMA), which may induce an enhanced anti-tumor immune response against BCMA-expressing tumor cells (PMID: 23344265).|
|Cyclophosphamide||Cytoxan||CPM||Chemotherapy - Alkylating 14||Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary).|
|Fludarabine||Fludara||FAMP|Fludarabine phosphate||Flurdara (fludarabine) is converted to 2-fluoro-ara-ATP intracellularly, which potentially inhibits DNA polymerase alpha, ribonucleotide reductase and DNA primase, leading to decreased DNA synthesis and reduced tumor growth (NCI Drug Dictionary)|
|LY3039478||Crenigacestat|LY-3039478||NOTCH Inhibitor (Pan) 5||Crenigacestat (LY3039478) is a pan-NOTCH inhibitor, which may limit growth and survival of cancer cells (Cancer Res April 15, 2013 73; 1131, PMID: 32042099).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03502577||Phase I||Anti-BCMA CAR T Cells + Cyclophosphamide + Fludarabine + LY3039478||BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma||Recruiting|